Although HDAC inhibitors have been reported to display a synergistic therapeutic effect on EGFR inhibitor resistant NSCLC cell lines when combined with EGFR inhibitors, possibly because of the downregulation of c-Met, the mechanisms remain far from clear. Here, MET is linked to non-small cell lung carcinoma.